NCT05651711: An ongoing trial by Amgen
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05651711 |
|---|---|
| Title | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 14, 2022 |
| Completion date | June 5, 2024 |
| Required reporting date | June 5, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |